Table 3.
Univariate Cox regression survival analysis for all CRC patients undergoing surgery (n = 125).
| Variables | OS | DFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (≥65 versus <65) | 1.469 | 0.596–3.622 | 0.404 | 1.405 | 0.660–2.991 | 0.378 |
| Gender (male versus female) | 1.952 | 0.703–5.424 | 0.191 | 1.692 | 0.740–3.865 | 0.212 |
| Smoking | 2.745 | 0.798–9.451 | 0.109 | 1.953 | 0.587–6.493 | 0.275 |
| Family history | 1.618 | 0.372–7.040 | 0.521 | 1.755 | 0.527–5.844 | 0.360 |
| Cancer site | 1.264 | 0.477–3.345 | 0.637 | 1.370 | 0.612–3.064 | 0.444 |
| Histologic class | 1.492 | 0.199–11.204 | 0.698 | 1.059 | 0.143–7.813 | 0.956 |
| Differentiation | 21.018 | 0–3707867.689 | 0.621 | 0.697 | 0.094–5.146 | 0.723 |
| Tumor stage | 4.491 | 1.308–15.418 | 0.017 | 3.049 | 1.231–7.557 | 0.016 |
| Tumor size (≥5 cm versus <5 cm) | 1.923 | 0.634–5.827 | 0.248 | 2.069 | 0.833–5.141 | 0.117 |
| Fib (≥3.30 g/mL versus <3.30 g/mL) | 1.092 | 0.429–2.777 | 0.853 | 1.263 | 0.567–2.812 | 0.568 |
| RBC | ||||||
| ≥4.43 versus <4.43 (×1012/mL) | 1.460 | 0.593–3.596 | 0.410 | 1.538 | 0.723–3.275 | 0.264 |
| PLR (≥113.5 versus <113.5) | 2.656 | 0.881–8.010 | 0.083 | 2.048 | 0.865–4.846 | 0.103 |
| NLR (≥2.43 versus <2.43) | 3.193 | 1.213–8.405 | 0.019 | 2.582 | 1.182–5.644 | 0.017 |
| CEA (≥5 ng/mL versus <5 ng/mL) | 4.351 | 1.645–11.509 | 0.003 | 4.023 | 1.803–8.974 | 0.001 |
| CA199 | ||||||
| ≥7.42 U/mL versus <5 U/mL | 2.496 | 0.828–7.520 | 0.104 | 1.602 | 0.701–3.660 | 0.264 |
AC = adenocarcinoma; NAC = nonadenocarcinoma; Fib = fibrinogen; RBC = red blood cell; PLR = platelet-to-lymphocyte ratio; NLR = neutrophil-to-lymphocyte ratio; CEA = carcinoembryonic antigen; CA199 = carbohydrate antigen 199; COCN = combination of CEA and NLR; HR = hazard ratio; OS = overall survival; DFS = disease-free survival.